Similar articles

• Phase I evaluation of chlorozotocin (NSC-178248): weekly schedule.

  Moriconi WJ, Taylor S, Slavik M, Belt RJ, Haas CD, Hoogstraten B. Moriconi WJ, et al. Invest New Drugs. 1985;3(1):57-62. doi: 10.1007/BF00176825. Invest New Drugs. 1985. PMID: 3157661
• Treatment of advanced soft tissue sarcoma with chlorozotocin: a phase II trial of the EORTC soft tissue and bone sarcoma group.

  Mouridsen HT, Bramwell VH, Lacave J, Metz R, Vendrik C, Hild J, McCreanney J, Sylvester R. Mouridsen HT, et al. Cancer Treat Rep. 1981 May-Jun;65(5-6):509-11. Cancer Treat Rep. 1981. PMID: 6453646
• Phase II trial with chlorozotocin in advanced colorectal cancer.

  Bleiberg H, Rozencweig M, Michel J, Clavel M, Longeval E, Feremans W, Bondue H, Lardinois J, Crespeigne N, Kenis Y. Bleiberg H, et al. Eur J Cancer Clin Oncol. 1981 Aug;17(8):863-6. doi: 10.1016/0014-2964(81)90306-6. Eur J Cancer Clin Oncol. 1981. PMID: 6459936 No abstract available.
• Current status of nitrosoureas under development in Japan.

  Ogawa M, Fujimoto S. Ogawa M, et al. Recent Results Cancer Res. 1981;76:115-24. doi: 10.1007/978-3-642-81565-2_10. Recent Results Cancer Res. 1981. PMID: 6453413 Review. No abstract available.
• Chlorozotocin.

  [No authors listed] [No authors listed] IARC Monogr Eval Carcinog Risks Hum. 1990;50:65-75. IARC Monogr Eval Carcinog Risks Hum. 1990. PMID: 2149865 Free PMC article. Review. No abstract available.